GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Capex-to-Revenue

BerGenBio ASA (OSL:BGBIO) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

BerGenBio ASA's Capital Expenditure for the three months ended in Mar. 2024 was kr0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was kr0.17 Mil.

Hence, BerGenBio ASA's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


BerGenBio ASA Capex-to-Revenue Historical Data

The historical data trend for BerGenBio ASA's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Capex-to-Revenue Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only - 0.11 - - -

BerGenBio ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BerGenBio ASA's Capex-to-Revenue

For the Biotechnology subindustry, BerGenBio ASA's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BerGenBio ASA's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BerGenBio ASA's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where BerGenBio ASA's Capex-to-Revenue falls into.



BerGenBio ASA Capex-to-Revenue Calculation

BerGenBio ASA's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.354
=0.00

BerGenBio ASA's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.167
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BerGenBio ASA  (OSL:BGBIO) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


BerGenBio ASA Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BerGenBio ASA (OSL:BGBIO) Business Description

Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines